Diana A van der Plaat1, Kim de Jong1, Lies Lahousse2, Alen Faiz3, Judith M Vonk1, Cleo C van Diemen4, Ivana Nedeljkovic5, Najaf Amin5, Guy G Brusselle6, Albert Hofman5, Corry-Anke Brandsma3, Yohan Bossé7, Don D Sin8, David C Nickle9, Cornelia M van Duijn5, Dirkje S Postma10, H Marike Boezen11. 1. Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 2. Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands; Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium. 3. Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 4. Department of Genetics, University of Groningen, University Medical Center Groningen, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 5. Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands. 6. Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands; Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. 7. Department of Molecular, Medicine, Laval University, Institut universitaire de cardiologie et de pneumologie de Québec, Quebec City, Quebec, Canada. 8. Department of Medicine, Division of Respiratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; University of British Columbia Center for Heart Lung Innovation, St Paul's Hospital, Vancouver, British Columbia, Canada. 9. Merck & Co, MRL, Seattle, Wash. 10. Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 11. Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: h.m.boezen@umcg.nl.
Abstract
BACKGROUND: Although a striking proportion (25% to 45%) of patients with chronic obstructive pulmonary disease are never-smokers, most genetic susceptibility studies have not focused on this group exclusively. OBJECTIVE: The aim of this study was to identify common genetic variants associated with FEV1 and its ratio to forced vital capacity (FVC) in never-smokers. METHODS: Genome-wide association studies were performed in 5070 never-smokers of the identification cohort LifeLines, and results (P < 10-5) were verified by using a meta-analysis of the Vlagtwedde-Vlaardingen study and the Rotterdam Study I-III (total n = 1966). Furthermore, we aimed to assess the effects of the replicated variants in more detail by performing genetic risk score, expression quantitative trait loci, and variant*ever-smoking interaction analyses. RESULTS: We identified associations between the FEV1/FVC ratio and 5 common genetic variants in the identification cohort, and 2 of these associations were replicated. The 2 variants annotated to the genes hedgehog interacting protein (HHIP) and family with sequence similarity 13 member A (FAM13A) were shown to have an additive effect on FEV1/FVC levels in the genetic risk score analysis; were associated with gene expression of HHIP and FAM13A in lung tissue, respectively; and were genome-wide significant in a meta-analysis including both identification and 4 verification cohorts (P < 2.19 × 10-7). Finally, we did not identify significant interactions between the variants and ever smoking. Results of the FEV1 identification analysis were not replicated. CONCLUSION: The genes HHIP and FAM13A confer a risk for airway obstruction in general that is not driven exclusively by cigarette smoking, which is the main risk factor for chronic obstructive pulmonary disease.
BACKGROUND: Although a striking proportion (25% to 45%) of patients with chronic obstructive pulmonary disease are never-smokers, most genetic susceptibility studies have not focused on this group exclusively. OBJECTIVE: The aim of this study was to identify common genetic variants associated with FEV1 and its ratio to forced vital capacity (FVC) in never-smokers. METHODS: Genome-wide association studies were performed in 5070 never-smokers of the identification cohort LifeLines, and results (P < 10-5) were verified by using a meta-analysis of the Vlagtwedde-Vlaardingen study and the Rotterdam Study I-III (total n = 1966). Furthermore, we aimed to assess the effects of the replicated variants in more detail by performing genetic risk score, expression quantitative trait loci, and variant*ever-smoking interaction analyses. RESULTS: We identified associations between the FEV1/FVC ratio and 5 common genetic variants in the identification cohort, and 2 of these associations were replicated. The 2 variants annotated to the genes hedgehog interacting protein (HHIP) and family with sequence similarity 13 member A (FAM13A) were shown to have an additive effect on FEV1/FVC levels in the genetic risk score analysis; were associated with gene expression of HHIP and FAM13A in lung tissue, respectively; and were genome-wide significant in a meta-analysis including both identification and 4 verification cohorts (P < 2.19 × 10-7). Finally, we did not identify significant interactions between the variants and ever smoking. Results of the FEV1 identification analysis were not replicated. CONCLUSION: The genes HHIP and FAM13A confer a risk for airway obstruction in general that is not driven exclusively by cigarette smoking, which is the main risk factor for chronic obstructive pulmonary disease.
Authors: Vijaya Karoor; Mehdi A Fini; Zoe Loomis; Timothy Sullivan; Louis B Hersh; Evgenia Gerasimovskaya; David Irwin; Edward C Dempsey Journal: Arterioscler Thromb Vasc Biol Date: 2017-11-30 Impact factor: 8.311
Authors: Paolo B Dominelli; Chad C Wiggins; Tuhin K Roy; Timothy W Secomb; Timothy B Curry; Michael J Joyner Journal: Mayo Clin Proc Date: 2021-03-11 Impact factor: 7.616
Authors: Rachel Zeig-Owens; Ankura Singh; Thomas K Aldrich; Charles B Hall; Theresa Schwartz; Mayris P Webber; Hillel W Cohen; Kerry J Kelly; Anna Nolan; David J Prezant; Michael D Weiden Journal: Ann Am Thorac Soc Date: 2018-02
Authors: Claudia Mazio; Laura S Scognamiglio; Rossella De Cegli; Luis J V Galietta; Diego Di Bernardo; Costantino Casale; Francesco Urciuolo; Giorgia Imparato; Paolo A Netti Journal: Cells Date: 2020-06-01 Impact factor: 6.600
Authors: Ivana Nedeljkovic; Natalie Terzikhan; Judith M Vonk; Diana A van der Plaat; Lies Lahousse; Cleo C van Diemen; Brian D Hobbs; Dandi Qiao; Michael H Cho; Guy G Brusselle; Dirkje S Postma; H M Boezen; Cornelia M van Duijn; Najaf Amin Journal: Front Genet Date: 2018-04-19 Impact factor: 4.599